Chordoma Disease Therapeutics Market Analysis | Coherent Market Insights Market Analysis | Coherent Market Insights

1
Coherent Market InsightS

• Market Research and Business Consulting
  Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
Inhaled Antibiotics Market Analysis (2020-2027)

• The management of patients with chronic
  respiratory diseases have become a challenge in
  clinical practice. Conditions such as cystic
  fibrosis (CF) and non-CF bronchiectasis require
  extensive treatment strategies to deal with
  multidrug resistant pathogens that include
  Pseudomonas aeruginosa, Methicillin-resistant
  Staphylococcus aureus, Burkholderia species, and
  non-tuberculous Mycobacteria (NTM).
• To overcome these challenges scientists are
  developed a noval drug formulation of
  antimicrobial agent and deliver drugs to the
  pulmonary system by using inhaled, aerosolized or
  nebulized antibiotics.

3

• The important application of inhaling antibiotics
  is to maximize drug delivery to the target site
  of infection i.e. the airways and limit the
  potential for systemic side effects.
• The global inhaled antibiotics market size was
  valued at US 1,094.6 million in 2019 and is
  expected to exhibit a CAGR of 6.3 over the
  forecast period (20202027).

4
Figure 1 Global Inhaled Antibiotics Market Value
(US Mn), by Region, 2020
5
Increasing incidence of respiratory diseases is
expected to drive the market growth over the
forecast period

• Increasing drug approvals from regulatory
  authorities for the treatment of chordoma is
  expected to drive growth of the chordoma disease
  therapeutics market over the forecast period.
• For instance, in May 2018, Bavarian Nordic A/S, a
  pharmaceutical company, received orphan drug
  designation from the U.S. Food and Drug
  Administration (FDA) for BN-Brachyury, a novel
  cancer vaccine indicated for the treatment of
  chordoma.  

6
Figure 2. Global Chordoma Disease Therapeutics
Market Share (), by Drug Class, 2020
7
Increasing adoption of strategies such as
mergers, agreements, and collaborations by key
players is expected to drive the market growth
over the forecast period

• Market players are focused on adoption of
  inorganic growth strategies such as
  collaborations and agreements to strengthen their
  position in the chordoma disease therapeutics
  market.
• For instance, in January 2019, Biothera
  Pharmaceuticals entered into a licensing
  agreement with Cipla Limited for its potential
  bevacizumab biosimilar, BAT1706. Through this
  agreement, Cipla Limited received the rights to
  distribute and market the biosimilar in emerging
  markets.

8
Chordoma Disease Therapeutics Market Restraint

• Chemotherapeutic drugs approved for the treatment
  of chordoma are not always effective and have
  several side effects such as nausea, headache,
  and hair loss, which is expected to restrain the
  market growth over the forecast period.
• Also, low prevalence of the disease and
  limitations associated with the treatment are
  factors affecting the market growth, followed by
  the high cost of diagnosis, treatment, and
  research development.

9
(No Transcript)
10
 Global Chordoma Disease Therapeutics Market
Impact of Coronavirus (Covid-19) Pandemic

• Treatment options of cancer such as chemotherapy
  can weaken the immune system of cancer patients
  and increases the risk of getting infected.
  Hence, people suffering from cancer such as
  chordoma are at higher risk of developing serious
  complications due to COVID-19 disease.
• However, considering the criticality of the
  chordoma disease it has been recommended by the
  regulatory authorities to not delay of postpone
  the chemotherapy or immunotherapy for the
  treatment of chordoma disease.

11

• Healthcare providers are adopting telehealth
  solutions to conduct their services for cancer
  patients while maintain the social distancing to
  combat COVID-19 pandemic without compromising the
  health of cancer patients. Patients can arrange
  virtual appointments with their doctors for
  consultations. Healthcare providers are taking
  following measures to reduce the spread of
  COVID-19 infection.
• Hospitals have restricted entries of visitors and
  only emergency cases are being handled.
• A screening for possible symptoms of COVID-19 is
  being performed for all the people who are
  entering the hospitals.
• Healthcare givers are encouraging patients to
  conduct patients schedule appointments via
  telemedicine platforms.

12
Key Players

• Major players operating in the global chordoma
  disease therapeutics market include
  GlaxoSmithKline Plc, Bavarian Nordic A/S,
  Boehringer Ingelheim International GmbH, Pfizer,
  Inc., Merck Co., Inc., Sanofi SA, Astellas
  Pharma Inc., AstraZeneca plc, Amgen, Inc.,
  Bristol-Myers Squibb and Company, Novartis
  International AG, Bayer AG, Dr. Reddys
  Laboratories Ltd., and Mylan N.V.

13

• Request sample copy here
• Request PDF brochure here
• Request Customization here
• Talk to Analyst
• Buy Now
• Reference
• https//www.coherentmarketinsights.com/market-insi
  ght/inhaled-antibiotics-market-3980

14
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

15
Contact Us   

• Mr. Shah
• Coherent Market Insights Pvt. Ltd.
• Address 1001 4th ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

16
Thank You!

• Kindly follow CMI Social Media Profiles for the
  latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/